BMS claimed rights to Krazati when it acquired Mirati Therapeutics last year in a $5.8 billion deal. So far, neither of the KRAS drugs have lived up to their initial sales expectations ...

Just nine months after announcing a massive plan to cut costs, Bristol Myers Squibb has gone one better, revealing a new goal to save even more money.

BridgeBio and BMS first started working together on studies ... as a monotherapy and is also in combination studies with Mirati's KRAS drug adagrasib. "We have seen the potential role SHP2 ...

Acquiring Mirati Therapeutics brings Bristol Myers Squibb Krazati, one of two FDA-approved therapies addressing a KRAS cancer mutation. The deal comes as BMS looks to add revenue-generating ...

Intravenous Opdivo, with $2.48 billion in sales, topped the list of precision oncology products in BMS's growth portfolio.